Therapeutic Drug Monitoring to Individualize the Dosing of Pazopanib-Reference-Cited by-同舟云学术

Therapeutic Drug Monitoring to Individualize the Dosing of Pazopanib

Published:2015-06 Issue:3 Volume:37 Page:331-338
ISSN:0163-4356
Container-title:Therapeutic Drug Monitoring
language:en
Short-container-title:

Author:

de Wit Djoeke,van Erp Nielka P.,den Hartigh Jan,Wolterbeek Ron,den Hollander-van Deursen Margret,Labots Mariëtte,Guchelaar Henk-Jan,Verheul Henk M.,Gelderblom Hans

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Pharmacology

Reference20 articles.

1. . Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.;Sternberg;J Clin Oncol,2010

2. . Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.;Van der Graaf;Lancet,2012

3. . Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.;Hutson;J Clin Oncol,2010

4. . Phase I trial of pazopanib in patients with advanced cancer.;Hurwitz;Clin Cancer Res,2009

5. . Moving towards dose individualization of tyrosine kinase inhibitors.;Klumpen;Cancer Treat Rev,2011

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Model-informed precision dosing: State of the art and future perspectives;Advanced Drug Delivery Reviews;2024-08

2. Therapeutic drug monitoring of osimertinib in EGFR mutant non‐small cell lung cancer by dried blood spot and plasma collection: A pilot study;British Journal of Clinical Pharmacology;2024-05-05

3. Therapeutic Drug Monitoring of Pazopanib in Renal Cell Carcinoma and Soft Tissue Sarcoma: A Systematic Review;Therapeutic Drug Monitoring;2024-04-30

4. Preliminary Investigation of a Rapid and Feasible Therapeutic Drug Monitoring Method for the Real-Time Estimation of Blood Pazopanib Concentrations;The AAPS Journal;2024-04-15

5. Therapeutic drug monitoring to personalize dosing of imatinib, sunitinib, and pazopanib: A mixed methods study on barriers and facilitators;Cancer Medicine;2023-10-30